InterStim™ Systems

THE RELIEF YOU’VE BEEN WAITING FOR

When lifestyle changes and medications fail, Medtronic bladder control therapy delivered by the InterStim™ systems can help. This therapy is simple and discreet, and it delivers the kind of relief that lets you enjoy the activities you love without a second thought.

Why Are Medtronic Therapies Different?

COMMUNICATION IS CRITICAL

Evidence suggests that breakdowns in the bladder-brain communication pathway are the root cause of OAB and non-obstructive urinary retention.^1-3 While more conservative therapies focus on the bladder muscles, Medtronic therapies target the nerves, which is thought to help restore normal bladder function.*

• Targets the nerves that control your bladder to help it function normally again
• 85% of people using the InterStim™ system achieved success in the first year^†,4 
• 3X greater improvements in quality of life compared to medications⁶
• Lets you see if it works before you and your doctor decide
• Allows you to get full-body MRI scans if you need them^‡
• Hundreds of thousands of people have experienced relief with this safe, FDA-approved and minimally invasive therapy

THE CHOICE IS YOURS

Medtronic bladder control therapy delivered by the InterStim™ systems offers recharge-free and rechargeable options, so you can choose the right one for your lifestyle.  

• The recharge-free InterStim™ II system may be best for most people because it’s simple, convenient, and low maintenance.
• The rechargeable InterStim™ Micro system is smaller, lasts longer, and requires regular recharging sessions.

Compare The Interstim™ II And Interstim™ Micro Systems For Medtronic Bladder Control

Read the Medtronic bladder control therapy brochure

---

* Defined as a 50% or greater reduction in your troublesome bladder symptoms.

† Numbers reflect completers analysis defined as patients with diary data at baseline and 12 months (n=220). Clinical success was 82% at 12 months using the modified completers analysis (subjects who either had a baseline and 12 month evaluation or withdrew early due to device-related reasons and are considered failures).

‡ Under certain conditions. See approved labeling for details. Patients with InterStimTM SureScanTM MRI leads only.

§ Battery life may vary based on therapy settings.

|| Under standard patient therapy settings and appropriate recharger placement.

¶ Reflects OAB patients.

# These patient groups were analyzed based on the treatment they were assigned: incomplete data was counted as ”failures.” Another analysis reported 61% of people achieved success with InterStim, compared to 42% who used medications.

** Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.

---

1. Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol. 2005;174:2268–2272.
2. Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862–1867.
3. Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466–474.
4. Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2016 Feb;35(2):246-51.
5. National Association for Continence. Overactive Bladder. www.nafc.org/overactive-bladder(opens new window). Accessed November 21, 2016.
6. Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim^® Therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–230.
7. Foster RT Sr, Anoia EJ, Webster GD, Amundsen CL. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn. 2007;26:213–217.
8. Visco A, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. New Engl J Med. 2012;367(19):1803–1813.
9. Peters KM, Carrico DJ, et al. “Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.” J Urol. 2010;183(4): 1438-1443.
10. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055-1061.